Objective: To determine whether complete cMyBP-C phosphorylation is dependent on Ser-282 phosphorylation and to define its role in myocardial function. We hypothesized that Ser-282 regulates Ser-302 phosphorylation and cardiac function during ␤-adrenergic stimulation. , were generated. Mutant protein was completely substituted for endogenous cMyBP-C by breeding each mouse line into a cMyBP-C null (t/t) background. Serine-to-alanine substitutions were used to ablate the abilities of the residues to be phosphorylated, whereas serine-to-aspartate substitutions were used to mimic the charged state conferred by phosphorylation. Compared to control nontransgenic mice, as well as transgenic mice expressing wild-type cMyBP-C, the transgenic cMyBP-C
of the contractile proteins may partially underlie cardiac dysfunction in heart failure. 4, 5 Cardiac myosin-binding protein-C (cMyBP-C) phosphorylation at multiple sites can impact myocardial function, 6, 7 metabolism, 8 and cardioprotection, 9 but the precise functional consequences of phosphorylation are not characterized fully. cMyBP-C is a 140-kDa structural protein that is localized at the inner two-thirds of the A-band in the cardiac sarcomere. 10, 11 cMyBP-C binds myosin at the S2 region 12 and light meromyosin, 13, 14 where it modulates myosin assembly 10 and actin-myosin interaction. 15, 16 It also binds to titin via domains C8 to C10 17 and presumably to actin as well; however, this interaction is less well-defined, 18 suggesting that these interactions may be necessary for the stability or function of cMyBP-C in the sarcomeres.
The cardiac isoform differs from the skeletal isoform in that it contains an extra domain at the N-terminus (C0) and a phosphorylation motif (M-domain) localized between the immunoglobulin I-like C1 and C2 domains, 19, 8 in which Ser-273, Ser-282, and Ser-302 each can be phosphorylated. 20 The three sites are differentially phosphorylated by the enzymes protein kinase (PK) A, 21 PKC, 21 Ca 2ϩ -calmodulinactivated kinase II (CaMKII), 19 PKD, 22 and the 90-kDa ribosomal s6 kinase. 23 To begin to explore the physiological roles of cMyBP-C phosphorylation, we previously established two transgenic (TG) mouse models in which the three phosphorylation sites were mutated to either alanine (phospho-ablation, AllPϪ) or aspartate (phospho-mimetic, AllPϩ). 7, 9, 24, 25 Our findings suggested that cMyBP-C phosphorylation was essential for normal cardiac function and that charged residues at 273, 282, and 302 sites conferred cardioprotection against ischemia-reperfusion injury in either the ␣-myosin heavy chain or the ␤-myosin heavy chain backgrounds. However, these data did not resolve the functional roles of the individual sites. Previously, hierarchical phosphorylation patterns for cMyBP-C have been defined in vitro, 19 where Ca 2ϩ -dependent CaMKII phosphorylation at Ser-282 appeared to be necessary for phosphorylation of Ser-273 and Ser-302. 19, 21, 26 Furthermore, monophosphorylation of cMyBP-C by CaMKII is associated with myocardial stunning 20 and enhanced contractility 27 under certain conditions. 26 However, the critical role of Ser-282 phosphorylation in vivo remains to be systematically investigated.
In the present study, we explored the necessity and sufficiency of Ser-282 phosphorylation in mediating cardiac structure and function using three TG mouse models in which mutated cMyBP-C replaced the endogenous cardiac protein. cMyBP-C carrying the mutations Ser273-Ala282-Ser302 (SAS), Ala273-Asp282-Ala302 (ADA), or Asp273-Ala282-Asp302 (DAD) were generated and expressed specifically in cardiomyocytes. Our data demonstrate that Ser-282 phosphorylation is a critical determinant of Ser-302 phosphorylation in vitro and in vivo and that phosphorylation at each of the residues participates in the contractile response to ␤-AR stimulation in vivo.
Methods

TG Constructs
cMyBP-C wild-type (WT) cDNA was subjected to site-directed mutagenesis to generate cMyBP-C SAS , cMyBP-C DAD , and cMyBP-C ADA constructs. Cardiomyocyte-specific TG mice were generated using the mouse cardiac-specific ␣-myosin heavy chain promoter. 7, 9 An N-terminal myc-tag, which has no effect on cMyBP-C function and stability, 7, 9, 28 was introduced to differentiate TG protein from endogenous cMyBP-C. All biochemical and functional assays used hearts from 10-to 12-week-old mice. Animals were handled in accordance with the principles and procedures of the Guide for the Care and Use of Laboratory Animals. The Institutional Animal Care and Use Committee at Cincinnati Children's Hospital approved all experimental procedures.
Characterization of TG Mice
TG mice were identified by polymerase chain reaction. 7 Transgene copy number was determined by southern blotting ( Figure I , online data supplement available online at http://circres.ahajournals.org) and transgene expression in the cardiomyocytes determined by real-time polymerase chain reaction and confirmed in some cases by northern blot analysis with a gene-specific ␥ 32 P-labeled probe 7 using actin and GAPDH as loading controls (Online Figure I) . To ensure that the observed phenotype was not attributable to insertional mutagenesis, at least two different TG lines were used from each group when assessing the functional consequences of complete cMyBP-C mutant protein replacement in the cMyBP-C (t/t) background. 7, 9 The presence of necrosis, fibrosis, and disarray, as well as localization and integration of cMyBP-C mutant proteins into the sarcomere, were evaluated by immunofluorescence microscopy as described. 7 To determine sarcomeric A-band, I-band, and M-line organization and thick filament distances, structural analyses at the light and electron microscopy levels were performed. 7,9
Evaluation of cMyBP-C Phosphorylation
To define the phosphorylation status of Ser-273, Ser-282, and Ser-302, myofibrils from nontransgenic (NTG) and TG mouse hearts were treated with either PKA, PKC, CaMKII␦, or phosphatase (Sigma), electrophoresed on SDS-PAGE, and Western blots were performed using an anti-cMyBP-C 2-14 antibody that was raised against the first 14 residues of cMyBP-C (ProSci) and phosphospecific cMyBP-C antibodies as described previously. 22, 24 In addition, the importance of each phosphorylation site was confirmed using recombinant human mutant C1-M-C2 peptides and sitespecific cMyBP-C phospho-antibodies. 22, 24 
Cardiac Function
Cardiac function was determined in the intact closed chest model as described. 7 Increasing doses of dobutamine were administered during 3-minute constant infusions (0.1 L/min/g body weight) to determine ␤-AR responsiveness. To observe changes in left ventricular chamber size and fractional shortening, noninvasive M-mode echocardiography was used. 9 
Non-standard Abbreviations and Acronyms
Statistical Analysis
All biochemical and functional assays were performed in mice obtained at 10 to 12 weeks of age along with mixed-gender controls. One-way ANOVA was used to test for overall significance, followed by the Student-Newman-Keuls test for multiple comparison testing between the various groups (Sigma Plot 11). Data are presented as meansϮSEM.
Results
Phosphorylation of Ser-282 Is Critical for Ser-302 Phosphorylation
We focused on three sites in the cardiac-specific insertion region of cMyBP-C to determine their roles in modulating cardiac function. Initially, to determine the substrate specificity of these sites by PKA, 21 PKC, 21 and CaMKII, 19 recombinant human His-tagged C1-M-C2 fragments of cMyBP-C were generated in which the three phosphorylatable sites were individually mutated to alanine, as well as a wild-type control ( Figure 1A ). 22 Peptides were treated with PKA, PKC, or CaMKII␦, and their phosphorylation status was determined by Western blot analysis using site-specific cMyBP-C phosphoantibodies ( Figure 1B, 1C) . Experiments with PKA-mediated and PKC-mediated phosphorylation confirmed that PKA phosphorylates all three sites, whereas PKC phosphorylates only Ser-273 and Ser-302 ( Figure 1C ). At low Ca 2ϩ concentrations, CaMKII␦ targets Ser-302, whereas at high Ca 2ϩ concentrations Ser-282 also can be a substrate (Online Figure I , available online at http://circres.ahajournals.org), confirming that Ca 2ϩ -dependent CaMKII differentially phosphorylates Ser-282 and Ser-302. Phosphorylation at Ser-282 appears to be required for Ser-302 phosphorylation in vitro ( Figure 1B, panel 4, antip302) .
To explore further the site-specificity of Ser-273, Ser-282, and Ser-302 for PKA, PKC, and CaMKII, we infected neonatal rat cardiomyocytes with adenovirus expressing constitutively active and dominant-negative forms of rat CaMKII␦C 29 and rabbit PKC. 30 Western blot analysis showed 10Ϯ2-fold overexpression of CaMKII␦ and 4Ϯ1.2-fold overexpression of PKC in neonatal rat cardiomyocytes ( Figure 1D, 1F ). Cardiomyocytes were treated with isoproterenol as a positive control for the PKA activation. We then performed Western blot analysis using our site-specific cMyBP-C phospho-antibodies 24 and compared those results with isoproterenol-treated cardiomyocytes as a positive control. 24 Results show that overexpression of constitutively active CaMKII␦ specifically increased Ser-302 phosphorylation compared to controls, confirming that Ser-302 is a substrate for CaMKII␦ ex vivo, whereas the PKC transfections confirmed that Ser-273 and Ser-302 are both PKC substrates ( Figure 1D-1G ). To demonstrate active regulation A, His 6 -tagged C1-M-C2 recombinant human cardiac myosin-binding protein-C (cMyBP-C) peptide that includes the C1-M-C2 domains with the three phosphorylation sites. In the normal endogenous protein, each of these three serines is phosphorylatable. B, The ability of each residue to be phosphorylated by protein kinase (PK) A, Ca 2ϩ -calmodulin-activated kinase II (CaMKII␦), or PKC is shown in (B) and (C), respectively. A dash indicates that the endogenous fragment with all three serines intact is present, and immunoblotting is indicated by "IB" (Western blotting). The mutation of serine (S) to alanine (A) at each residue is indicated as Ser to Ala. Phosphorylation of each residue with each enzyme was assayed using our phosphoresidue-specific antibodies via Western blot analyses. Ponceau-S staining of the membranes confirmed equal amounts of protein were loaded. D and E, Western blot analyses, using site-specific phospho cMyBP-C antibodies, of neonatal rat cardiomyocytes infected with constitutively active (CA) and dominant negative (DN) CaMKII␦ and (F and G) PKC adenoviruses (Ad) at a multiplicity of infection of 100 (nϭ5). C, Negative control using an empty vector for infection, isoproterenol-treated (ISO); 50 nmol/L ISO neonatal rat cardiomyocytes. H and I, At different time points after transverse aortic constriction (TAC) in mice, Western blot analysis of total heart proteins using site-specific phospho cMyBP-C antibodies demonstrated that phosphorylation increased significantly after 30 minutes, but that Ser-282 phosphorylation was significantly reduced after 24 hours compared to Ser-273 and Ser-302 sites (nϭ6). *PϽ0.01 vs control or sham (nϭ5).
of these sites during cardiac stress, a transverse aortic constriction-induced pressure-overload mouse model was used. Western blot analyses, using myofilament proteins from the transverse aortic constriction-induced pressure-overload model, showed that Ser-273 and Ser-302 phosphorylation was significantly increased after 5 minutes but decreased after 4 weeks of transverse aortic constriction ( Figure 1H, 1I ). In contrast, Ser-282 phosphorylation was significantly increased after 5 minutes but decreased after 24 hours, showing the sites were differentially regulated in terms of their steady-state phosphorylation levels. These in vivo experiments are consistent with the hypothesis that Ser-282 phosphorylation is an early event in the stressed heart but does not resolve the question of whether its posttranslational modification is necessary for the subsequent phosphorylation of the other sites. 19, 21 To resolve this question, we turned to the intact animal and replaced endogenous cMyBP-C with protein that could not be phosphorylated at Ser-282.
Three Transgenic Mouse Models
Three separate constructs were used to generate multiple lines of TG mice to test the hypothesis that Ser-282 phosphorylation influenced the phosphorylation levels of residue 302 (Figure 2A, 2B ). In the cMyBP-C SAS mouse model, Ser-282 of cMyBP-C was mutated to a nonphosphorylatable alanine, preventing Ser-282 phosphorylation. In the cMyBP-C ADA mouse model, the PKC sites (Ser-273 and Ser-302) were mutated to nonphosphorylatable alanines and Ser-282 was replaced with aspartate, resulting in a Ser-282 phosphomimetic. In contrast, the third mouse model, cMyBP-C DAD , contains charged residues (aspartates) at amino acids 273 and 302, mimicking constitutive PKC-mediated phosphorylation ) hearts. D, Expression levels of total cMyBP-C and the presence of myc-tagged (TG) cMyBP-C in the same mice were confirmed by Western blot analysis. E, Western blot analyses using phosphospecific antibodies on the in vitro dephosphorylated and phosphorylated NTG, cMyBP-C WT , and cMyBP-C SAS myofibrils with phosphatase (control), protein kinase (PK) C, PKA, and Ca 2ϩ -calmodulin-activated kinase II (CaMKII␦) treatment. PKA phosphorylates all three sites, whereas PKC phosphorylates Ser-273 and Ser-302. CaMKII␦ was used at two different Ca 2ϩ concentrations. F, Quantitative analysis of Western blot data (E). No significant differences were found between NTG and WT(t/t) groups. Values represent meansϮstandard error for each group (nϭ3), and designations denote significant differences (PϽ0.001) from *WT(t/t) and #controls.
in the absence of phosphorylation at Ser-282, resulting in Ser-282 phospho-ablation. All TG mice were characterized before crossing into the cMyBP-C (t/t) background to assess any effects of TG expression. In each TG mouse model, we obtained three lines with variable transgene expression, resulting in 25% to 45% replacement of the endogenous cMyBP-C with TG protein (Online Figure II) . None of the lines showed any obvious phenotype or increased morbidity and mortality over the course a 10-month period, suggesting that the SAS, ADA, and DAD mutations are benign in the unstressed animals (data not shown).
To obtain complete replacement of endogenous cMyBP-C with the TG mutant proteins, the individual cMyBP-C SAS , cMyBP-C ADA , and cMyBP-C DAD lines were bred into the cMyBP-C null background (t/t). 31 SDS-PAGE confirmed normal levels of cMyBP-C in this background, driven by transgenic expression of the mutant cMyBP-C and levels of other sarcomeric proteins, such as actin and myosin, were unaltered ( Figure 2C ). Using antibodies against the myctag as well as to the first 14 N-terminal residues of cMyBP-C, the incorporation of the mutant cMyBP-C into the sarcomere was confirmed as well as the ability of the protein to maintain the proper stoichiometry by Western blotting ( Figure 2D ).
To determine if elimination of Ser-282 phosphorylation affected Ser-302 phosphorylation, we treated myofilaments derived from cMyBP-C SAS(t/t) hearts with PKA, PKC, and CaMKII and determined the phosphorylation status of each residue by Western analyses using the residue-specific phospho-antibodies ( Figure 2E ). As expected, the Ser-282 site-specific phospho-antibody showed no reactivity under any conditions with cMyBP-C SAS(t/t) -derived protein. Strik- (DAD(t/t)) hearts. E, Transmission electron micrographs of sarcomeres show loss of the normal M-line structures in both cMyBP-C (t/t) and cMyBP-C DAD(t/t) hearts. For each line, between 240 and 539 individual sarcomeres were scored. For the control hearts, wild-type (WT) (t/t), 544 sarcomeres were counted with 9% blindly scored as "abnormal." For the Ser273-Ala282-Ser302 (SAS(t/t)) or Ala273-Asp282-Ala302 (ADA(t/t)) animals, 15% to 18% had abnormal M-lines, whereas for the DAD(t/t) animals 244 sarcomeres were counted and 83% had scores indicating abnormal M-lines. ingly, the loss of Ser-282 phosphorylation impacted significantly on the ability of PKA, PKC, and CaMKII to phosphorylate Ser-302 ( Figure 2E ). Specifically, CaMKII-mediated phosphorylation was completely abolished in the SAS myofilament preparations ( Figure 2E and Figure 4 ). To determine whether increased Ca 2ϩ concentrations could overcome this block in the phosphor-ablated cardiac sample, 25 mmol/L Ca 2ϩ was used with CaMKII to treat the cMyBP-C SAS(t/t) myofilaments. Western blot analyses showed that increased Ca 2ϩ concentrations can stimulate Ser-282 phosphorylation in the NTG and cMyBP-C WT(t/t) myofilaments, whereas Ser-302 phosphorylation in the absence of Ser-282 phosphorylation was reduced, with the site being hypophosphorylated relative to normal cMyBP-C ( Figure 2F ).
Sarcomere Architecture in the SAS, ADA, and DAD Mutant Hearts
We reported previously that expression of cMyBP-C WT(t/t) and cMyBP-C AllPϩ(t/t) effectively rescued the cMyBP-C (t/t)
phenotype, but that expression of the nonphosphorylatable cMyBP-C AllPϪ failed to rescue the null, suggesting the necessity of cMyBP-C phosphorylation for normal sarcomere and cardiac function. 7, 9 To explore this observation at the individual residue level, we first determined whether the phospho-specific mutants incorporated normally into the sarcomere. Immunohistochemical analyses were performed with both anti-myc and anti-cMyBP-C antibodies ( Figure 3A, 3B) . Results show that SAS, ADA, and DAD proteins were incorporated normally into the sarcomere in the cMyBP-C (t/t) mouse background with striations indistinguishable from those seen in the NTG and cMyBP-C WT(t/t) sarcomeres ( Figure 3A, 3B) . Histological analyses showed that, as expected, the cMyBP-C (t/t) hearts displayed cardiac hypertrophy with fibrosis and disarray. However, there were no obvious abnormalities, fibrosis, calcification, or disarray observed in the cMyBP-C SAS(t/t) and cMyBP-C ADA(t/t) samples compared to NTG and cMyBP-C WT(t/t) controls ( Figure  3C and 3D ). In contrast with these data, the cMyBP-C DAD(t/t) mouse hearts showed fibrosis and disarray, mimicking the cMyBP-C t/t phenotype. Considering that this mouse contains the cMyBP-C phospho-mimetic in which residues 273 and 302 are constitutively charged, the data emphasize the importance of Ser-282 phosphorylation for cMyBP-C function. Transmission electron microscopy confirmed the previous observations of subtle organizational changes at the center of the sarcomere, at the M-line, and in the cMyBP-C-null mice, with the characteristic electron-dense M-line largely absent or irregular ( Figure 3E) . 7, 9, 31 Consistent with the lack of disarray and fibrosis observed in the cMyBP-C WT(t/t)
, cMyBP-C SAS(t/t)
, and cMyBP-C ADA(t/t) hearts, the center of those sarcomeres contained a well-defined M line that was indistinguishable from those observed in normal sarcomeres in 81% to 91% of the sarcomeres. In contrast, 83% of the cMyBP-C DAD(t/t) sarcomeres displayed significant M-line abnormalities, suggesting that Ser-282 phosphorylation is necessary for the structural functions of cMyBP-C. The heart-to-body weight ratios were normal in cMyBP-C SAS(t/t) (0.57Ϯ0.02) and cMyBP-C ADA(t/t) (0.57Ϯ0.02) mice compared to cMyBP-C WT(t/t) (0.56Ϯ0.02) and NTG (0.50Ϯ0.013) controls at 3 months. Consistent with the histology, cMyBP-C DAD(t/t) mouse hearts showed significantly increased heart-to-body weight ratios (0.70Ϯ0.015, PϽ0.0001 vs NTG), as did the cMyBP-C (t/t) hearts (0.81Ϯ0.02, PϽ0.0001 vs NTG), 7 but with normal systolic function ( Table 1) . In contrast, cMyBP-C ADA(t/t) mice showed normal heart-to-body weight ratios but reduced systolic function, suggesting that phospho-specific mutations have differential effects on cardiac structure and function. M-mode echocardiographic measurements showed that expression of normal cMyBP-C (cMyBP-C WT(t/t) ) rescued the cMyBP-C (t/t) phenotype as previously shown (Table 1) . 7, 9 In contrast to those data, cMyBP-C SAS(t/t) , cMyBP-C ADA(t/t) , and cMyBP-C DAD(t/t) mice showed only partial rescue of the null phenotype. Each model had significantly increased intraventricular septal thickness and left ventricular end-diastolic and endsystolic dimensions ( Table 1 ), indicating that none was as effective at restoring normal cardiac hemodynamics as the WT protein (Table 1 ). The cMyBP-C SAS(t/t) , cMyBP-C DAD(t/t) and cMyBP-C ADA(t/t) hearts, all showed reduced fractional shortening, although only the cMyBP-C ADA(t/t) hearts reached statistical significance. These data suggest that phosphorylation at Ser-273, Ser-282, and Ser-302, individually or in combination, is required for normal cardiac function to be maintained long-term.
␤-AR Stimulation and cMyBP-C Phosphorylation
Phospho-ablation at Ser-282 attenuates Ser-302 phosphorylation, and we hypothesized that this would critically impact the ability of the heart to respond to ␤-AR stimulation. The cMyBP-C SAS(t/t) hearts contain only cMyBP-C SAS cMyBP-C, allowing us to determine the functional consequence of the inability of Ser-282 to be phosphorylated in vivo during ␤-AR stimulation. We noted that Ser-273 appeared to be hyperphosphorylated in the cMyBP-C SAS hearts at baseline, in contrast to the hypophosphorylation observed at Ser-302 ( Figure 4A, 4B) . At baseline, all groups showed normal systolic function, suggesting that mutating the three selected phosphorylation sites does not affect systolic function (Table  2) . On ␤-AR stimulation (dobutamine infusion), a reduced response was observed in all of the TG hearts, with the exception of those animals expressing the normal cMyBP-C protein (cMyBP-C WT/(t/t) ). The cMyBP-C SAS(t/t) hearts further showed significantly decreased phosphorylation at Ser-302 during ␤-agonist stimulation compared to NTG and cMyBP-C WT:(t/t) controls, confirming the importance of Ser-282 phosphorylation in mediating Ser-302 phosphorylation as well ( Figure 4C) . Interestingly, the mice containing phosphor-mimetics (cMyBP-C DAD:(t/t) ) and phospho-ablation (cMyBP-C ADA:(t/t) ) at residues 273 and 302 could not respond normally to dobutamine, emphasizing the importance of normal and, potentially, reversible phosphorylation at each of the three sites in mediating normal function and ␤-agonistϪinduced stimulation. ADA indicates Ala273-Asp282-Ala302; DAD, Asp273-Ala282-Asp302; dP/dt max , maximum rate of heart contraction and relaxtion; dP/dt min , minimum rate of heart contraction and relaxtion; EDP, end-diastolic pressure; LV, left ventricular; LVP, left ventricular pressure; NTG, nontransgenic; MAP, mean arterial pressure; SAS, Ser273-Ala282-Ser302; WT, wild-type.
Ventricular contraction and relaxation rates were measured at baseline and during ␤-agonist stimulation in the intact closed chest model, including telemetric measurements of heart rate, MAP, LV systolic pressure and LVEDP, LVP, ϩdP/dt max , ϪdP/dt min , and the rate of LVP increase determined at an LVP of 40 mm Hg (dP/dt 40 ). Cardiovascular stress response to increasing doses of dobutamine was determined during 3-minute constant infusions (0.1 L/min/g body weight), and data were analyzed using a PowerLab system (AD Instruments). Data are presented as meanϮSE.
*PϽ0.05; †PϽ0.005 compared with NTG; ‡PϽ0.05; §PϽ0.005; ¶PϽ0.0005 compared with (t/t).
Discussion
Increasing data suggest that cMyBP-C phosphorylation can regulate myocardial function, 7 sarcomere integrity, 9 and, in some cases, can be cardioprotective. 9, 25 It is currently the only thick filament protein that is differentially phosphorylated by five important kinases ( Figure 5 ) that can impact on cardiac contraction: PKA, 21 PKC, 21 CaMKII, 19 PKD, 22 and ribosomal s6 kinase. 23 Our present study focused on deciphering the phosphorylation pattern of cMyBP-C and determining which phosphorylatable sites are necessary or perhaps sufficient for normal cardiac function. Although cMyBP-C is extensively phosphorylated under basal conditions, the level of cMyBP-C phosphorylation decreases in animal models during development of heart failure, myocardial injury, pathological hypertrophy, and myocardial stunning. 5, 20, 24, 32, 33 Previously, to better-understand the mechanisms and significance of cMyBP-C phosphorylation, we established two TG mouse models to determine the necessity and sufficiency of cMyBP-C for normal cardiac function. 7, 9 Our findings showed that cMyBP-C phosphorylation is essential for normal cardiac function 7 and that a phospho-mimetic at the Ser-273, Ser-282, and Ser-302 phosphorylation sites conferred cardioprotection against myocardial ischemia reperfusion injury in either the ␣-myosin heavy chain 9 or ␤-myosin heavy chain backgrounds. 24 Phosphorylation of Ser-282 was a focus of the present study because phosphorylation levels of this residue are decreased in patients with heart failure 32,34 and atrial fibrillation. 4 Strikingly, Ser-282 is also selectively phosphorylated by ribosomal s6 kinase, which regulates myofilament function. 23 In vitro studies demonstrated that phosphorylation at Ser-282 is a prerequisite for phosphorylation of the Ser-273 and Ser-302 sites. 19, 21 The data obtained from those studies also showed that the ability to phosphorylate Ser-273 and Ser-302 is markedly reduced when Ser-282 is mutated to alanine, suggesting that hierarchical phosphorylation may be involved in cMyBP-C-mediated regulation of contraction in cardiac muscle. In the present study, we removed the ability of Ser-282 to be phosphorylated to investigate the importance of Ser-282 phosphorylation in maintaining normal cardiac function at the whole organ function. Our data demonstrate that Ser-282 regulates the subsequent phosphorylation of Ser-302, but not Ser-273. 19, 21, 22 We hypothesize that Ser-282 is both a regulatory and functional site for phosphorylation, with the cMyBP-C DAD:(t/t) mice showing significant pathology at the light and ultrastructural levels ( Figure 3D, 3E) .
cMyBP-C is a substrate for PKC, which can phosphorylate Ser-273 and Ser-302 in cardiomyocytes. 21 PKC can also phosphorylate cMyBP-C, 35 and this series of enzymes, some more selective than others, makes cMyBP-C phosphorylation exquisitely responsive to the changing environment. cMyBP-C phosphorylation, which is partially mediated by PKC, appears to play a critical role in cardiac function. 9 However, the roles of these sites in cardiac physiology have not been characterized. PKC phosphorylation mediates a major mechanism by which the myofilament modulates cMyBP-C is the 140-kDa-thick filament sarcomeric proteins that consists of 11 domains; 8 immunoglobulin (oval), and 3 fibronectin type III (square) domains. The C0 domain, phosphorylation motif (m), and a cardiac-unique insertion in the C5 domain are unique (light green) to cMyBP-C when compared to skeletal MyBP-C. The proline-rich/alanine-rich region (Pro-Ala) and hypothesized actin and myosin binding sites are marked. The three phosphorylation motifs, Ser-282, Ser-273, and Ser-302, are shown (reference to the mouse identification number), which are targeted by protein kinase (PK) A, 21 PKC, 21 Ca 2ϩ -calmodulin-activated kinase II (CaMKII), 19 PKD, 22 and the 90-kDa ribosomal s6 kinase (RSK). 23 Amino acid sequences are numbered using Uniprot and National Center for Biotechnology Information reference numbers. Note that Ser-282 in the mouse corresponds to Ser-284 in the human sequence.
changes in myocardial function. 35 Gautel et al 19 obtained in vitro evidence that phosphorylation of Ser-282 may potentiate the PKC phosphorylation sites (Ser-273 and Ser-302), and thus phosphorylation could function as a switch that might also be triggered to mediate accelerated cardiac function during ␤-AR activation. Evidence from other studies suggests that cMyBP-C phosphorylation influences actomyosin Mg 2ϩ -ATPase activity, the kinetics of cross-bridge cycling, and the rate of relaxation. 19,36 -38 Therefore, the second objective of the study was to assess the necessity and sufficiency of PKC-mediated cMyBP-C phosphorylation for sarcomeric integrity and for normal cardiac function. cMyBP-C ADA(t/t) and cMyBP-C DAD(t/t) hearts showed decreased hemodynamics and contractility relative to cMyBP-C WT(t/t) controls during ␤-AR stimulation because of the constitutive phosphoablation or phospho-mimetic "phosphorylation" (charged residues) of the PKC phosphorylation sites in cMyBP-C.
Importantly, cMyBP-C ADA(t/t) mice unambiguously showed the effect of Ser-282 phosphorylation in the absence of PKC site phosphorylation on whole organ anatomy and function and partially rescued the cMyBP-C (t/t) phenotype. Conversely, despite the charged residues at Ser-273 and Ser-302, the cMyBP-C DAD(t/t) hearts displayed extensive damage compared to cMyBP-C ADA(t/t) and cMyBP-C SAS(t/t) mice and damage to cellular components ( Figure 3 ) and had hypertrophy over time, mimicking the t/t null phenotype. Why do the cMyBP-C DAD(t/t) hearts display more overt abnormal pathology than the cMyBP-C SAS(t/t) mice when residue 282 is mutated in both? Overexpression of PKC isoforms in the heart causes hypertrophy in adult mice. 39 We hypothesize that mimicking constitutive activation of these two PKC sites in cMyBP-C by replacing the two serines with aspartates in the cMyBP-C DAD(t/t) cardiomyocytes is detrimental to the hearts. In contrast, serines 273 and 302 in the cMyBP-C SAS(t/t) will not behave as if they were chronically phosphorylated; in fact, serine 302 will be hypophosphorylated in these hearts and thus not exhibit the effects of chronic phosphorylation, as manifested both by a hypertrophic response and a decreased M-line definition.
Conclusion
In conclusion, our data confirm the critical importance of Ser-282 in maintaining normal cardiac ( Figure 3C, 3D ) and sarcomere ( Figure 3E ) architecture regardless of the phosphorylation status of the PKC sites. These data provide strong evidence that cMyBP-C phosphorylation directly affects the heart's contractile properties and sarcomere organization.
